A 0.5 mg dose of colchicine, a drug commonly used for conditions such as gout, was recently approved by the FDA to prevent cardiovascular events in patients with residual inflammatory risk.It is the first anti-inflammatory agent to be approved as an atheroprotective CV treatment, according to a press release from the manufacturer, and is expected to be available later this year. News of the
A new analysis has shown a particularly large reduction in CV events and death with lipid-lowering therapy in the primary prevention population, leading to calls for more attention to be paid to this group.
The FDA has given the new low dose of colchicine a broad indication for use in atherosclerotic cardiovascular disease, but how will the drug actually be used in clinical practice?
FDA Approves Colchicine for Decreasing CV Events tctmd.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tctmd.com Daily Mail and Mail on Sunday newspapers.